VivoSeq
Other

Periodontitis

86

Pipeline Programs↗

34

Active Trials↗

31

Companies Involved↗

Periodontitis is a moderately active landscape with 86 programs across 31 companies. The most active players are Cerimon Pharmaceuticals, Taiwan Bio Therapeutics Inc., Roche. 29 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

42/100

Mech. Concentration

28/100

Completion Rate

97/100

Attrition Rate

2/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cerimon Pharmaceuticals

1 program

Phase 1T

Taiwan Bio Therapeutics Inc.

1 program

Phase 1Roche logo

Roche

1 program

Phase 1P

Pascoe Pharmazeutische Praeparate GmbH

1 program

Phase 1G

Geistlich Pharma AG

1 program

Phase 2N

Noveome Biotherapeutics, formerly Stemnion

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical12

Chlorhexidine Gluconate

Medline Industries

Platelet-Rich Fibrin (PRF)

Federal University of São Paulo

Propolis

Indonesia University

Spirulina

Tanta University

Antipsychotic Drugs Inducing Hyperprolactinemia

Fayoum University

Phase 16

Diclofenac Sodium

Cerimon Pharmaceuticals

Sargramostim

Sanofi

Ketorolac Tromethamine

Roche

Quercetin

Mayo Clinic

Bromelain

Indiana University

Phase 223

Glutamine

Sanofi

Atorvastatin Calcium

Merck & Co.

Aspirin

Bayer

Melatonin

Neurim Pharmaceuticals Ltd.

Bleeding and Clots

TC Erciyes University

Phase 316

Curcumin

Merck & Co.

Calcium Hydroxide

Mansoura University

Chlorhexidine

Dexcel Pharma Technologies Ltd.

Fluoride

GSK

Clindamycin

Pfizer

Approved29

Nitazoxanide

Romark Laboratories L.C.

Valacyclovir

Glaxo Dba Glaxosmithkline

Ibuprofen

Kenvue Brands

Ketoprofen

Wyeth-Lederle Vaccines

Cyclosporine

Novartis

Analysis

Modality Breakdown

98%

Small molecule

120 of 123 classified programs — the dominant modality here.

2%ALL OTHERSProtein / enzyme22%Cell therapy1<1%

Small molecule leads; the ring shows all 123 classified programs, each share of the total. Modality classified for 98% of 139 pipeline programs.

Analysis

Trial Status

133

clinical trials

Completed75 · 56%
Unknown status22 · 17%
Not yet recruiting11 · 8%
Recruiting11 · 8%
Active, not recruiting10 · 8%
Terminated2 · 2%
Other2 · 2%

Clinical Trials

Trial Activity

133 trials

Contribution of an Antiviral Drug (Valaciclovir) in the Treatment of Generalized Periodontitis (Stage III or IV and Grade A, B or C): Prospective, Randomized and Double Blind Clinical Trial
Recruiting·—·Phase 3·NCT05902208·142 enrolled
3-Month Clinical Trial of Liquid S-PRF in Periodontal Debridement for Periodontitis Stages II-IV
Recruiting·MMahsa University·Phase 2·NCT07293962·14 enrolled
Antimicrobial Photodynamic Therapy With ICG-Loaded Nanoparticles for Periodontitis Management
Recruiting·—·Phase 2·NCT07316023·27 enrolled
Evaluation Of The Efficacy Of Subgingival Application Of Lovastatin Gel As An Adjunct To Non-Surgical Treatment Of Periodontitis In Generally Healthy Smokers And Non-Smokers Patients in Central Europe.
Recruiting·MMedical University of Silesia·N/A·NCT07282756·44 enrolled
Evaluation of 2%Bromelain Gel With 0.2%CHX Gel as Subgingival LDD Following SRP in Stage II/III and Grade B Periodontitis -A RCT
Recruiting·KKrishnadevaraya College of Dental Sciences & Hospital·Phase 1·NCT06505759·36 enrolled
Effectiveness of Asiaticoside as Intracanal Medication on Infectious/Inflammatory Contents in Teeth With Apical Periodontitis
Recruiting·MMansoura University·Phase 2/3·NCT06566508·36 enrolled
Therapeutic Effect of Manuka Honey Oral Rinse in Periodontitis Patients Undergoing Hemodialysis
Recruiting·—·Phase 3·NCT06726876·150 enrolled
Investigate"Clinically" the Effectiveness of Boswellia Based Intracanal Medication Compared to Calcium Hydroxide Ca(OH)2 and Ledermix on the Levels of Bacteria and Inflammatory Cytokines in Root Canals and Periradicular Tissues of Teeth With Apical Periodontitis
Recruiting·MMansoura University·Phase 2/3·NCT06466538·36 enrolled
Platelet Rich Fibrin Adjunctive to Non-surgical Periodontal Therapy: a 6-month Split-mouth Randomized Controlled Clinical Trial
Recruiting·UUniversity of Bern·Preclinical·NCT07013682·20 enrolled
Comparative Clinical Efficacy and Microbiological Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Severe Periodontitis
Recruiting·TThe University of Hong Kong·Preclinical·NCT06967402·60 enrolled
Evaluation of the Effects of Anti-inflammatory Nutrition on the Outcomes of Non-surgical Periodontal Therapy in Individuals With Periodontitis
Recruiting·Recep Tayyip Erdogan University Training and Research Hospital·N/A·NCT07287540·100 enrolled
Evaluation of the Influence of PRF (Platelet-rich Fibrin) on the Clinical Parameters and the Concentration of Selected Inflammation Mediators in GCF (Gingival Crevice Fluid) of Patients With Periodontitis
Active, not recruiting·MMedical University of Bialystok·N/A·NCT06920849·40 enrolled
N-acetylcysteine for Root Canal Treatment of Necrotic Teeth With Apical Periodontitis
Active, not recruiting·—·Phase 2·NCT07262554·40 enrolled
The Proposed Study Aims to Investigate the Efficacy of Quercetin as an Adjunctive to Mechanical Debridement in Treatment of Periodontitis
Active, not recruiting·MMansoura University·Phase 2·NCT06982248·60 enrolled
Clinical and Laboratory Evaluation of Resveratrol Loaded Nanoparticles in the Treatment of Periodontitis: A Randomized Controlled Clinical Trial
Active, not recruiting·HHagar Ahmed Ali Mohammed Elzain·Phase 1·NCT07397026·48 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)